Skip to main content
. 2020 Jun 26;10:916. doi: 10.3389/fonc.2020.00916

Figure 1.

Figure 1

Relative expression of CORO2A in malignant and non-malignant breast tissues. (A) Relative expression of CORO2A in malignant and non-malignant breast tissues in four GEO datasets, GSE21422, GSE29431, GSE42568, and GSE61304. Data are mean ± SEM. Student's t-test (unpaired) was adopted to compare the statistical significance. ***P < 0.001. Panels (B–H) show CORO2A transcript in subgroups of patients with breast cancer, stratified based on age of diagnosis, gender, and other criteria (UALCAN). (B) Relative expression of CORO2A in normal and breast cancer samples. (C) Relative expression of CORO2A in normal individuals or in breast cancer patients with different age. (D) Relative expression of CORO2A in normal individuals or in breast cancer patients with differential ethnicity. (E) Relative expression of CORO2A in normal individuals or in breast cancer patients with differential tumors stages. (F) Relative expression of CORO2A in normal individuals or in breast cancer patients with differential nodal metastatic status. (G) Relative expression of CORO2A in normal individuals or in breast cancer patients with differential tumors subclasses. (H) Relative expression of CORO2A in normal individuals or breast cancer patients with differential menopause status. Data are mean ± SEM. **P < 0.01; ***P < 0.001. (I) Comparison of CORO2A mRNA expression between breast cancer tissues and paracancerous tissues (n = 22). β-actin was used as an internal reference gene for normalization. Data were analyzed using paired Student's t-test.